REVENUE RECOGNITION AND RELATED ALLOWANCES - Disaggregation (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Disaggregation of Revenue [Line Items]
Total net revenues	$ 137,430	$ 106,786
Sales of generic pharmaceutical products
Disaggregation of Revenue [Line Items]
Total net revenues	70,217	63,713
Sales of established brand pharmaceutical products, royalties, and other pharmaceutical services
Disaggregation of Revenue [Line Items]
Total net revenues	30,276	26,743
Sales of rare disease pharmaceutical products
Disaggregation of Revenue [Line Items]
Total net revenues	$ 36,937	$ 16,330